To Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection in Males

Inclusion Criteria

• •1. Male patients, aged 18-75 years old;
• •2. Preoperative breast ultrasound indicates male breast development, and breast enlargement symptoms persist for more than 1 year;
• •3. Primary male breast development that has been unresponsive to drug treatment, or those who refuse drug treatment;
• •4. According to Gynecomastia's surgical indications, refer to the "2023 Expert consensus on the clinicaldiagnosis and treatment of gynecomastia in China" Simon grading of male breast development IIb or above;
• •5. Due to social pressure or severe psychological burden caused by symptoms such as breast pain, those who have a strong desire for surgery may experience psychological burden caused by the disease and actively request surgery;
• •6. Individuals without serious accompanying diseases;
• •7. Suspected malignant transformation;
• •8. No other serious underlying diseases in the past;
• •9. The surgical procedure includes a single hole robot (intraperitoneal endoscopic single hole surgical system SP1000) for subcutaneous gland resection of the breast;
• •10. Participants are able to understand the research process, voluntarily join the study, sign informed consent forms, have good compliance, and cooperate with follow-up;
• •11. No swallowing difficulties; No shoulder joint movement disorders;
• •12. Complete clinical data.